UMMC Navigation

Available Trials

Main Content

Genitourinary Cancer

For more information regarding these studies, contact Cancer Research & Registry at (601) 984-1095.

Neoadjuvant: High-risk Clinically-localized Prostate

RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

This study is being done to compare the effects of hormone therapy (androgen deprivation) and radiation therapy to the prostate gland and seminal vesicles to hormone therapy and radiation therapy to the whole pelvic body area to find out which is better.

Principal Investigator: Srinivasan Vijayakumar, MD

 

Advanced Kidney/Renal

S1500: A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

This randomized phase II study to find out how well cabozantinib-s-malate, crizotinib, volitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib-s-malate, crizotinib, volitinib, and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Principal Investigator: John C. Henegan, MD

Bladder

No trials for bladder cancer are being conducted at UMMC/UMHC.